Erlotinib versus standard chemotherapy as first-line treatment for Euro- pean patients with advanced EGFR mutation- positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246. [6] Pao W, Miller VA, Politi KA, Riely GJ...
Rearrangements of theROS1gene occur in 1–2 % of non-small cell lung cancers (NSCLCs). Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the treatment of patients with advancedROS1-positive NSCLC. Consequently, focus onROS1testing is growing. Most lab...